A consortium‑driven framework for expanding access to interventional neurosurgical cell therapy for Parkinson's disease
Cell and Gene Therapy Insights · 25.06.2026 · 12 (5) · 523–536
DOI: 10.18609/cgti.2026.062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 25.06.2026. Verfasst von Howard J Federoff und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Parkinson's disease (PD) is a compelling target for dopaminergic cell-replacement therapy. Transitioning PD cell therapy from academic medical center trials to broad clinical availability requires coordinated solutions across manufacturing, surgical delivery, regulatory alignment, reimbursement, workforce development, and long-term infrastructure. This Expert Insight proposes a consortium-driven framework to expand access to interventional neurosurgical cell therapy for PD through a coherent, end-to-end delivery ecosystem linking standardized products, a tiered delivery network, scalable manufacturing, unified quality systems, parallel regulatory and payer engagement, and a mandatory longitudinal registry – offering a practical pathway to transition PD cell therapy from a small-batch, site-specific intervention to a reproducible, scalable, and equitable component of modern neurological care.
Zitieren
APA
Federoff, H. J., & Yartseva, V. (2026). A consortium‑driven framework for expanding access to interventional neurosurgical cell therapy for Parkinson's disease. Cell and Gene Therapy Insights, 12(5), 523–536. https://doi.org/10.18609/cgti.2026.062
Vancouver
Federoff HJ, Yartseva V. A consortium‑driven framework for expanding access to interventional neurosurgical cell therapy for Parkinson's disease. Cell and Gene Therapy Insights. 2026;12(5):523–536. doi:10.18609/cgti.2026.062
BibTeX
@article{Federoff2026,
author = {Federoff, Howard J and Yartseva, Valeria},
title = {A consortium‑driven framework for expanding access to interventional neurosurgical cell therapy for Parkinson's disease},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {5},
pages = {523–536},
doi = {10.18609/cgti.2026.062}
}
EUVIMED